SCHEMBL2175185

SCHEMBL2175185

Nc1cc(Nc2cccc([N+](=O)[O-])c2)nc(C2CCCCC2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 1/20 0.53
ABCC1 P33527 1/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
CTSL P07711 1/20 0.48
CTSB P07858 1/20 0.48
CTSS P25774 1/20 0.48
CTSK P43235 1/20 0.48
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
LMNA P02545 1/20 0.46
PIK3CA P42336 1/20 0.46
MTOR P42345 1/20 0.46
PRKDC P78527 1/20 0.46
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 3/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175875 0.77 GALR2 (0.56) ROCK1ABCC1ABCG2NPC1RAB9A
SCHEMBL9340413 0.72 ABCG2 (0.68) ABCC1ABCG2CTSLCTSBCTSS
SCHEMBL12485644 0.71 CTSL (0.57) ROCK1ABCG2CTSLCTSBCTSS
SCHEMBL3068523 0.71 ABCC1 (0.68) ROCK1ABCC1ABCG2NPC1RAB9A
SCHEMBL2177922 0.70 RAB9A (0.51) ABCG2CTSLCTSSCTSKRAB9A
SCHEMBL12968982 0.69 ROCK1 (1.00) ROCK1ABCC1ABCG2NPC1RAB9A
SCHEMBL29671292 0.69 ROCK1 (1.00) ROCK1ABCC1ABCG2NPC1RAB9A
SCHEMBL3475933 0.69 NPC1 (0.67) ABCG2CTSLCTSBCTSSCTSK
SCHEMBL394734 0.69 KMT2A (0.67) ROCK1ABCG2NPC1RAB9ALMNA
SCHEMBL16649499 0.69 RAB9A (0.52) RAB9ALMNAPIK3CAMTORPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2519501-B1 SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS UNIV WIEN TECH (AT) 2015-04-22 EP claimed
US-8986994-B2 Substituted pyridines and pyrimidines TECHNISCHE UNIVERSITAET WIEN (AT) 2015-03-24 US claimed
US-20120294835-A1 SUBSTITUTED PYRIDINES AND PYRIMIDINES MEDIZINISCHE UNIVERSITAET WIEN (AT) 2012-11-22 US claimed
EP-2519501-B1 SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS UNIV WIEN TECH (AT) 2015-04-22 EP disclosed
US-8986994-B2 Substituted pyridines and pyrimidines TECHNISCHE UNIVERSITAET WIEN (AT) 2015-03-24 US disclosed
US-20120294835-A1 SUBSTITUTED PYRIDINES AND PYRIMIDINES MEDIZINISCHE UNIVERSITAET WIEN (AT) 2012-11-22 US disclosed
EP-2519501-A2 SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS Technische Universität Wien (AT) 2012-11-07 EP disclosed
WO-2011079343-A2 SUBSTITUTED PYRIDINES AND PYRIMIDINES TECHNISCHE UNIVERSITAET WIEN (AT) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120294835-A1 SUBSTITUTED PYRIDINES AND PYRIMIDINES TNNI3, TNNT2, PROX1 ROCK1 1658/4885ABCC1 579/4885ABCG2 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.